Key opinion leaders review the evolution of Ph+ ALL treatment, from Hyper-CVAD to novel TKIs, blinatumomab, and deintensification, improving remission rates and survival.
The Messenger - The News in Brief messenger.com.ge - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from messenger.com.ge Daily Mail and Mail on Sunday newspapers.
Expert Elias Jabbour, MD, reviews clinical data from the PhALLCON study of ponatinib vs imatinib in patients with Ph+ acute lymphocytic leukemia and considers its clinical implications.
/PRNewswire/ Cancer & Hematology Centers of Western Michigan (CHCWM) has launched a Cancer Drug Repository (CDR) program to accept qualified unused oral.